Stirling products to test growth promotors in sheep.

By Renate Krelle
Wednesday, 30 June, 2004

Perth-based Stirling Products (ASX:STI) is preparing for the first animal trials of its ST810 growth promotion agent in sheep.

This trial will test the affect of ST810's -- a beta-2 agonist -- on tissue weight gain and carcass quality. In published scientific literature beta-agonists have been reported to increase lean meat in sheep from 15 to 35 per cent and reduce carcass fat from 25 to 45 per cent.

Because it is a pure 'single enantiomer' molecule, rather than a mix of right and left-handed enantiomers, STA-810 stimulates only beta-2 receptors. Current growth promotant products are both beta-1 and beta-2 agonists. Selectively stimulating beta-2 receptors may mean decreased side-effects, as beta-1 agonists are associated with increased heart rate.

The trial is scheduled to commence in early spring following trial protocol and animal ethics submissions.

Shares in Stirling were up 5 per cent to AUD$0.205.

Related News

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd